Public Health And Economic Benefits Of Quadrivalent Influenza Vaccine In Mexico

Abstract

studies. Outcome measures were life years, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICER). Future costs and outcomes being discounted at 3% per annum. Probabilistic sensitivity analysis (PSA) was conducted to deal with uncertainties around parameters. Results: The third regimen, 3) DRV/ r+RAL+TDF+3TC, was the lowest lifetime cost, which was 5.7 million baht, and approximately increased 10 QALYs. The incremental cost-effectiveness ratio for the third regimen compared with current practice was ฿ 332,227. ConClusions: All alternative regimens for treatment experienced patients with HIV drug resistance in Thailand were not currently cost-effective at the willingness to pay (WTP) 160,000 baht/QALYs.